From: Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma
Variables | Full cohort (n = 51) | R-CHOP cohort (n = 43) |
---|---|---|
Number of cases (%) | Number of cases (%) | |
Age, years | ||
 Mean (range) | 59.6 (21–85) |  |
  < 60 | 21 (41%) | 17 (40%) |
  ≥ 60 | 30 (59%) | 26 (60%) |
Sex | ||
 Male | 30 (59%) | 24 (56%) |
 Female | 21 (41%) | 19 (44%) |
Primary site | ||
 Nodal | 18 (35%) | 14 (33%) |
 Extranodal | 33 (65%) | 29 (67%) |
Ann Arbor stage | ||
 I, II | 27 (53%) | 23 (54%) |
 III, IV | 24 (37%) | 20 (46%) |
IPI groupa | ||
 Low (0–2) | 30 (60%) | 27 (63%) |
 High (3–5) | 20 (40%) | 16 (37%) |
B symptomsa | ||
 Absent | 31 (62%) | 29 (67%) |
 Present | 19 (38%) | 14 (33%) |
ECOG PSa | ||
 0, 1 | 40 (82%) | 37 (86%) |
 ≥ 2 | 9 (18%) | 6 (14%) |
LDHa | ||
 Normal | 21 (42%) | 19 (44%) |
 Elevated | 29 (58%) | 24 (56%) |
BM involvementa | ||
 Absent | 42 (91%) | 38 (93%) |
 Present | 4 (9%) | 3 (7%) |
Number of extranodal sitesa | ||
 0, 1 | 40 (80%) | 33 (77%) |
 ≥ 2 | 10 (20%) | 10 (23%) |
EBER | ||
 Negative | 40 (78%) | 36 (84%) |
 Positive | 11 (22%) | 7 (16%) |
Hans classification | ||
 GCB | 14 (27%) | 12 (28%) |
 Non-GCB | 37 (73%) | 31 (72%) |
Treatment | ||
 Rituximab + CHOP | 43 (84%) | 43 (100%) |
 Rituximab + others | 1 (2%) | 0 (0%) |
 Surgery only | 2 (4%) | 0 (0%) |
 No Tx | 5 (10%) | 0 (0%) |